ABSTRACT
No disponible
Subject(s)
Humans , Female , Zika Virus , Zika Virus/isolation & purification , Zika Virus/pathogenicity , Zika Virus Infection/epidemiology , Zika Virus Infection/prevention & control , Infectious Disease Incubation Period , Zika Virus Infection/physiopathology , Vector Control of Diseases , Sexually Transmitted Diseases, Viral/complications , Sexually Transmitted Diseases, Viral/epidemiology , Microcephaly/complications , Guillain-Barre Syndrome , Encephalitis/complications , Breast FeedingABSTRACT
The main objective in the management of HIV-infected pregnant women is prevention of mother-to-child transmission; therefore, it is essential to provide universal antiretroviral treatment, regardless of CD4 count. All pregnant women must receive adequate information and undergo HIV serology testing at the first visit. If the serological status is unknown at the time of delivery, or in the immediate postpartum, HIV serology testing has to be performed as soon as possible. In this document, recommendations are made regarding the health of the mother and from the perspective of minimizing mother-to-child transmission.
Subject(s)
HIV Infections/prevention & control , HIV Infections/transmission , Infectious Disease Transmission, Vertical/prevention & control , Pregnancy Complications, Infectious/prevention & control , Female , Humans , Infant, Newborn , PregnancyABSTRACT
Fundamento y objetivo: Fulvestrant es un antiestrógeno puro que ha demostrado eficacia en cáncer de mama avanzado como tratamiento de segunda línea tras progresión a tamoxifeno. El objetivo del trabajo fue describir la experiencia clínica con fulvestrant y evaluar su eficacia y tolerabilidad. Material y método: 36 mujeres posmenopáusicas con cáncer de mama avanzado recibieron tratamiento con fulvestrant. El 62,8% de las pacientes recibió fulvestrant al menos en tercera línea. Resultados: El 91,4% había recibido tratamiento hormonal previo en la enfermedad avanzada y más del 50%, quimioterapia. La enfermedad metastásica fue visceral en un 5,7%, no visceral en un 54,3% y en ambas localizaciones en un 40%. Se obtuvo un 11,4% de respuestas parciales (RP), un 22,9% presentó estabilidad de la enfermedad (EE), alcanzando beneficio clínico (BC) el 31,4% de las pacientes. La mediana de tiempo a la progresión (TTP) fue de 4,18 meses (intervalo de confianza del 95% [IC] del 95%, 2,65,7 meses), mientras que la mediana de supervivencia global (SG) no se ha alcanzado, con una mediana de seguimiento de 8,9 meses. Se produjeron eventos adversos de grado III en un 22,9% de las pacientes. Conclusiones: Fulvestrant es un fármaco bien tolerado, que representa una eficaz opción de tratamiento hormonal en el cáncer de mama avanzado intensamente tratado con hormonoterapia y quimioterapia (AU)
Background and objective: Fulvestrant (Flv) is a pure antiestrogen without agonist activity. Flv is effective as second line treatment in postmenopausal women with advanced breast cancer after tamoxifen. Material and method: We performed a retrospective study of 36 consecutive postmenopausal women treated with Flv and advanced breast cancer progressing on prior therapies. 62,8% received Flv as third line treatment or more (all patients had previously received endocrine treatment for early or advanced breast cancer), 54,3% adjuvant chemotherapy and 67,5% received chemotherapy for metastatic disease. Our objective was to analyze the response rate, clinical benefit, time to progression (TTP) and toxicity profile. Results: In our study 11,4% patients had partial responses (PR) and 22,9% had a stable disease (SD) >24 weeks. Clinical benefit rate (CB) [RP+RC+SD]: 31,4%. TTP: 4,2 months (CI 95%, 2,65,8), with a median follow-up of 8,9 months. Flv was well tolerated, 22,9% patients had adverse events, all grade I/II, and only 5,7% of women gave up the treatment. Conclusions: These data demonstrate that Flv is an effective and safe therapy for heavily pre-treated postmenopausal women with advanced breast cancer (AU)
Subject(s)
Humans , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms/drug therapy , Carcinoma, Ductal, Breast/drug therapy , Carcinoma, Lobular/drug therapy , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/pathology , Carcinoma, Lobular/pathology , Follow-Up Studies , Neoplasm Metastasis , Neoplasm Staging , PostmenopauseABSTRACT
BACKGROUND AND OBJECTIVE: Fulvestrant (Flv) is a pure antiestrogen without agonist activity. Flv is effective as second line treatment in postmenopausal women with advanced breast cancer after tamoxifen. MATERIAL AND METHOD: We performed a retrospective study of 36 consecutive postmenopausal women treated with Flv and advanced breast cancer progressing on prior therapies. 62,8% received Flv as third line treatment or more (all patients had previously received endocrine treatment for early or advanced breast cancer), 54,3% adjuvant chemotherapy and 67,5% received chemotherapy for metastatic disease. Our objective was to analyze the response rate, clinical benefit, time to progression (TTP) and toxicity profile. RESULTS: In our study 11,4% patients had partial responses (PR) and 22,9% had a stable disease (SD) >24 weeks. Clinical benefit rate (CB) [RP+RC+SD]: 31,4%. TTP: 4,2 months (CI 95%, 2,6-5,8), with a median follow-up of 8,9 months. Flv was well tolerated, 22,9% patients had adverse events, all grade I/II, and only 5,7% of women gave up the treatment. CONCLUSIONS: These data demonstrate that Flv is an effective and safe therapy for heavily pre-treated postmenopausal women with advanced breast cancer.
Subject(s)
Antineoplastic Agents, Hormonal/therapeutic use , Breast Neoplasms/drug therapy , Carcinoma, Ductal, Breast/drug therapy , Carcinoma, Lobular/drug therapy , Estradiol/analogs & derivatives , Estrogen Antagonists/therapeutic use , Adult , Aged , Aged, 80 and over , Antineoplastic Agents, Hormonal/administration & dosage , Breast/pathology , Breast Neoplasms/mortality , Breast Neoplasms/pathology , Carcinoma, Ductal, Breast/pathology , Carcinoma, Lobular/pathology , Estradiol/administration & dosage , Estradiol/adverse effects , Estradiol/therapeutic use , Estrogen Antagonists/administration & dosage , Estrogen Antagonists/adverse effects , Female , Follow-Up Studies , Fulvestrant , Humans , Kaplan-Meier Estimate , Middle Aged , Neoplasm Metastasis , Neoplasm Staging , Postmenopause , Retrospective Studies , Time Factors , Treatment OutcomeABSTRACT
Primary ovarian Burkitt lymphoma (BL) is a rare neoplasm in adults. We report a 30-year-old woman diagnosed with primary bilateral ovarian BL. She presented features of a twisted ovarian cyst and underwent bilateral salpingo-oophorectomy. The histopathologic evaluation yielded the diagnosis of BL and subsequently she received chemoimmunotherapy with CODOX-M-IVAC plus rituximab (anti-CD20 monoclonal antibody).
